KeyBanc analyst Scott Schoenhaus maintains $Recursion Pharmaceuticals (RXRX.US)$ with a buy rating, and adjusts the target price from $12 to $10.
According to TipRanks data, the analyst has a success rate of 37.1% and a total average return of -2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Recursion Pharmaceuticals (RXRX.US)$'s main analysts recently are as follows:
Political and rate uncertainty persist as concerns, yet the general condition of the Biopharma sector is seen as significantly better compared to its lowest points in 2022. Analysts express a preference for stocks that feature late-stage clinical or early launch narratives. Additionally, those in Phase 1 clinical programs that present derisking data along with near-term catalysts are gaining growing attention among investors.
The firm highlighted that healthcare technology stocks experienced significant pressure throughout much of last year but witnessed a rebound in the final two months following the presidential election. Alongside cuts to consensus estimates since mid-last year, the analyst deems 2025 as presenting attractive investment opportunities within the sector. From the standpoint of valuation multiples, the analyst surmises that companies boasting robust balance sheets and consistent free cash flow will face diminished risks of multiple contraction amidst more subdued growth outlooks. On the flip side, they view companies with strained balance sheets and scant near-term profitability as carrying heightened risks moving forward.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
KeyBanc分析師Scott Schoenhaus維持$Recursion Pharmaceuticals (RXRX.US)$買入評級，並將目標價從12美元下調至10美元。
根據TipRanks數據顯示，該分析師近一年總勝率為37.1%，總平均回報率為-2.7%。
此外，綜合報道，$Recursion Pharmaceuticals (RXRX.US)$近期主要分析師觀點如下：
政治和利率的不確定性仍然令人擔憂，但與2022年的最低點相比，生物製藥行業的總體狀況被認爲要好得多。分析師表示偏愛以後期臨牀或早期上市敘事爲特色的股票。此外，那些在第一階段臨牀項目中提供去風險數據和短期催化劑的人越來越受到投資者的關注。
該公司強調，醫療保健科技股在去年的大部分時間裏都承受了巨大的壓力，但在總統大選後的最後兩個月中出現了反彈。除了自去年年中以來下調共識預期外，分析師還認爲2025年爲該行業提供了有吸引力的投資機會。從估值倍數的角度來看，分析師推測，在增長前景更加疲軟的情況下，擁有強勁資產負債表和持續自由現金流的公司面臨的多重收縮風險將降低。另一方面，他們認爲資產負債表緊張且短期盈利能力不足的公司面臨更大的未來風險。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
